Synlait Milk Limited has issued a response to The a2 Milk Company’s trading update, confirming that it too has experienced significant operational challenges in the infant formula sector during the first half of 2026. The announcement reveals that Synlait implemented enhanced testing across all infant formula products earlier this year, a measure that has extended product release times and placed pressure on working capital requirements. This development underscores the mounting complexity surrounding product certification and regulatory compliance in China’s infant formula market, an issue that extends beyond Synlait to affect its major customer The a2 Milk Company.
The announcement provides insight into the cascading nature of supply chain disruptions affecting the infant formula industry. Synlait notes that it has been working through associated supply chain impacts with support from The a2 Milk Company, while simultaneously rebuilding customer inventory following previously reported manufacturing challenges. The company confirms that production has recently returned to targeted levels, suggesting some stabilisation after earlier disruptions. However, the fact that inventory rebuilding remains ongoing indicates that the sector has not yet fully normalised, with downstream customers likely still operating with constrained stock levels.
Notably, Synlait declined to provide financial guidance for the full year 2026 in its September 2025 results announcement, a decision that takes on additional significance in light of this latest update. The company’s response reinforces the breadth of headwinds currently facing infant formula manufacturers, extending well beyond the enhanced testing protocols. Product release and clearance times continue to affect the timing of sales and cash flow realisation, supply chain management remains complex, and the broader geopolitical and trading environment presents ongoing uncertainty. These factors collectively suggest that earnings visibility remains low and volatility in financial outcomes is likely to persist.
For investors holding positions in Synlait or considering exposure to the company, this announcement serves as a reminder of the structural challenges confronting the infant formula industry, particularly regarding exposure to China. Regulatory scrutiny in the Chinese market shows no signs of diminishing, and the extended testing requirements appear to be a permanent feature of the operating environment rather than a temporary measure. The ability of manufacturers to navigate these regulatory requirements while managing supply chain complexity and geopolitical uncertainty will be critical to determining profitability over the coming years.
Attention should focus on the pace at which customer inventory levels normalise and whether enhanced testing protocols stabilise at current levels or become subject to further changes. Commentary from management regarding the sustainability of production levels and visibility on product clearance timelines in the coming quarters will provide important indicators of the trajectory ahead. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About Synlait Milk Limited (ASX: SM1)
Synlait Milk Limited manufactures, processes, and sells dairy and non-dairy products including milk powder, fresh milk, cheese, butter, and nutritional products across China, Asia, the Middle East, Africa, New Zealand, Australia, and internationally. The company operates through two segments, Synlait and Dairyworks, serving bakeries, cafes, beverage chains, and manufacturers.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
